<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1516">
  <stage>Registered</stage>
  <submitdate>1/04/2007</submitdate>
  <approvaldate>1/04/2007</approvaldate>
  <nctid>NCT00455117</nctid>
  <trial_identification>
    <studytitle>Effect of Parecoxib on Post-craniotomy Pain</studytitle>
    <scientifictitle>Phase Four Study of Intravenous Parecoxib on Post-craniotomy Pain</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Parecoxib_HREC2006.133</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Anaesthesia</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Intravenous Parecoxib ('Dynastat' Pfizer)

Placebo Comparator: 1 - placebo (2 ml normal saline) administered intravenously at dural closure during craniotomy

Active Comparator: 2 - parecoxib 40 mg in 2 ml normal saline administered intravenously at dural closure during craniotomy


Treatment: drugs: Intravenous Parecoxib ('Dynastat' Pfizer)
parecoxib or placebo

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Morphine consumption in 24 hour period.</outcome>
      <timepoint>24 hours after surgery</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Immediate post-operative hypertension (first 2 hours)</outcome>
      <timepoint>24 hours after surgery</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pain scores at zero (time of extubation), 1, 2, 4, 12, 24 hours post operatively</outcome>
      <timepoint>24 hours after surgery</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Analgesic efficacy at 24 hours</outcome>
      <timepoint>24 hours after surgery</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of post-operative nausea and vomiting (first 24 hours)</outcome>
      <timepoint>24 hours after surgery</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Sedation or respiratory depression (first 24 hours)</outcome>
      <timepoint>24 hours after surgery</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Safety Monitoring (Serious adverse side effects)</outcome>
      <timepoint>24 hours after surgery</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Post-operative AMI</outcome>
      <timepoint>24 hours after surgery</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Post-operative renal failure</outcome>
      <timepoint>24 hours after surgery</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Post-operative thromboembolic stroke</outcome>
      <timepoint>24 hours after surgery</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Post-operative intracranial haemorrhage</outcome>
      <timepoint>24 hours after surgery</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Supratentorial craniotomy, glasgow coma scale 15</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Chronic pain,

          -  Chronic opioid use.

          -  History of significant alcohol or benzodiazepine (BZD) use,

          -  Inability to speak English,

          -  Pre-operative aphasia or dysphasia,

          -  Renal impairment (Creatinine level &gt; 0.1),

          -  Asthma (or evidence of reversible airway obstruction,

          -  Known ischaemic heart disease or cerebrovascular disease,

          -  American Society of Anaesthesiologists (ASA) grade IV or V,

          -  Allergy to any study drug (paracetamol, parecoxib, sulphas, morphine, bupivacaine,
             propofol, remifentanil;

          -  Administration of oral paracetamol within previous 8 hours.

          -  Pregnancy or breastfeeding</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3>The people assessing the outcomes</masking3>
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>1/09/2006</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>130</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/12/2008</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Royal Melbourne Hospital - Melbourne</hospital>
    <postcode>3050 - Melbourne</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Melbourne Health</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>Aim of this trial:

      To investigate whether post-craniotomy analgesia with (i) intravenous (IV) parecoxib plus
      intravenous paracetamol is superior to (ii) intravenous paracetamol alone.

      Study Hypothesis:

      Post-operative analgesia with intravenous parecoxib in combination with intravenous
      paracetamol will be superior to intravenous paracetamol alone.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00455117</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Daryl L Williams, MBBS</name>
      <address>Director of Anaesthesia, Royal Melbourne Hospital</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>